PolyPid Q1 Earnings Call Highlights

PolyPid NASDAQ: PYPD said its first quarter marked a transition from late-stage clinical development toward regulatory submission and commercial preparation for D-PLEX100, its lead product candidate for preventing surgical site infections in abdominal colorectal surgery.